LoVo Xenograft Model Service for Colon Cancer

The LoVo Xenograft Model Service for Colon Cancer provides a robust preclinical platform for evaluating therapeutic efficacy against metastatic colorectal adenocarcinoma, leveraging the clinically relevant KRAS G13D and MSI-H molecular profile of the LoVo cell line. At Alfa Cytology, we deliver validated LoVo xenograft models constructed under stringent quality standards to accelerate your oncology drug development pipeline with reproducible, data-rich in vivo studies.

Overview of LoVo Xenograft Model for Colon Cancer

The LoVo cell line was originally isolated in 1976 by Drewinko et al. from a metastatic tumor nodule in the left supraclavicular region of a 56-year-old male patient with colorectal adenocarcinoma. As a well-differentiated epithelial line, LoVo retains key intestinal cell properties including acinar structure formation, microvilli, glycocalyx, and intact desmosomal and tight junctions, making it a physiologically representative model for colorectal malignancy. Genetically, LoVo harbors an activating KRAS G13D mutation, wild-type BRAF, and microsatellite instability-high (MSI-H) status due to mismatch repair deficiency, aligning it with the CMS1 (MSI-Immune) consensus molecular subtype frequently observed in proximal colon cancers with high immunogenicity.

In xenograft applications, LoVo tumors reliably recapitulate the aggressive growth dynamics and molecular characteristics of the parental line, including upregulation of thymidylate synthase and ATP-binding cassette transporters associated with 5-fluorouracil resistance. The model has been extensively utilized to investigate cetuximab-mediated antibody-dependent cellular cytotoxicity, survivin-targeted apoptosis induction, and anti-angiogenic therapy responses. LoVo xenografts exhibit robust tumorigenicity in immunocompromised hosts, with demonstrated epithelial-mesenchymal transition features upon TGF-beta stimulation, providing a versatile platform for studying drug resistance mechanisms, metastatic dissemination, and tumor vascular biology in colorectal cancer.

Figure 1. Inhibition of colorectal adenocarcinoma cell viability by milk-deltaVB. (D'Onofrio, N, et al., 2020)

Cell Line Information: LoVo

The following table summarizes the comprehensive molecular, phenotypic, and culture characteristics of the LoVo cell line essential for preclinical xenograft model design and interpretation.

Our Services

Alfa Cytology provides end-to-end LoVo xenograft model services encompassing cell line authentication, in vivo model construction, treatment administration, longitudinal tumor monitoring, and comprehensive endpoint analysis including histopathology, immunohistochemistry, and molecular profiling. Our experienced team ensures IACUC-compliant study execution with rigorous quality control to generate reliable, publication-ready data for your colon cancer therapeutic programs.

Workflow of LoVo Xenograft Model Construction

The construction of LoVo xenograft models follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and reliable therapeutic evaluation. Each stage incorporates stringent monitoring and documentation to maintain model integrity throughout the study duration.

1. Cell Line Preparation and Quality Control: LoVo cells are revived from authenticated master stocks and cultured under standard conditions (Ham's F-12K supplemented with 10% FBS). Cells are tested for mycoplasma contamination, viability (typically >95% by trypan blue exclusion), and short tandem repeat (STR) profile confirmation prior to inoculation.
2. Host Selection and Acclimatization: Immunocompromised mice (commonly athymic BALB/c nude mice or NOD-SCID strains, 6-8 weeks old, 18-22 g) are acclimatized for 5-7 days under SPF conditions with controlled temperature, humidity, and 12-hour light/dark cycles.
3. Cell Suspension Preparation: LoVo cells are harvested at logarithmic growth phase, washed with sterile PBS, and resuspended at a concentration of 1 x 10^7 cells/mL in serum-free medium. For subcutaneous models, the suspension is mixed 1:1 with high-concentration Matrigel to enhance engraftment efficiency.
4. Tumor Inoculation: A total of 1 x 10^6 viable LoVo cells (0.1 mL volume) are injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle. For metastatic models, cells are administered via tail vein injection (1 x 10^6 cells in 0.2 mL PBS) to simulate hematogenous dissemination.
5. Tumor Monitoring and Randomization: Tumors are monitored by digital caliper measurement every 2-3 days beginning at day 7 post-inoculation. Tumor volume is calculated using the formula V = 0.5 x length x (width)^2. Mice are randomized into treatment cohorts when tumors reach 100-200 mm^3 (typical window: days 10-14).
6. Treatment Administration: Test compounds are administered according to predefined dosing regimens (route, frequency, and duration established per protocol). Concurrent vehicle control groups receive equivalent volumes of formulation buffer. Body weights and clinical signs are recorded throughout the treatment phase.
7. Endpoint Assessment and Tissue Collection: Upon reaching study endpoint (typically tumor volume 1000-1500 mm^3 or predetermined study duration), mice are humanely euthanized. Tumors are excised, weighed, and processed for downstream analyses including H&E histopathology, immunohistochemistry (Ki-67, CD31, TUNEL), and molecular profiling (RT-PCR, Western blot).

Figure 2: Schematic workflow illustrating the derivation and construction of the LoVo Xenograft Model at Alfa Cytology.

Case Study-LoVo Xenograft Model Development

In a representative preclinical evaluation, LoVo xenografts were established in immunocompromised mice and subjected to a multi-arm therapeutic study investigating novel anti-cancer agents targeting resistance pathways. Tumor-bearing animals demonstrated consistent engraftment rates exceeding 90%, with palpable tumors appearing within 10-14 days post-inoculation. Treatment arms showed differential responses in tumor growth inhibition, with select agents achieving significant tumor growth delay compared to vehicle controls. Comprehensive endpoint analysis revealed modulation of key signaling pathways including EGFR, survivin, and angiogenic markers. Detailed quantitative data, statistical analyses, and histopathological findings are available upon formal inquiry. Please contact our scientific team to discuss specific study parameters and access the complete dataset.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational excellence to deliver LoVo xenograft models that meet the highest standards of preclinical oncology research. Our integrated service platform ensures seamless execution from study design to data delivery.

• Validated, authenticated LoVo cell lines with confirmed KRAS G13D and MSI-H molecular profiles ensure model fidelity.
• IACUC-compliant animal facilities with SPF housing conditions guarantee welfare standards and data reproducibility.
• Customizable study designs accommodate diverse therapeutic modalities including small molecules, biologics, and combination regimens.
• Comprehensive endpoint analysis encompassing histopathology, IHC, flow cytometry, and molecular profiling provides mechanistic insights.
• Dedicated project management ensures transparent communication, milestone tracking, and on-time delivery of study reports.
• Competitive timelines with rapid model establishment (10-14 days to randomization) accelerate your drug development pipeline.

Contact Us

Ready to advance your colon cancer therapeutic program with our LoVo Xenograft Model Service? Contact us today to discuss your specific study requirements, receive a detailed proposal, and learn how Alfa Cytology can accelerate your preclinical research. Reach out to our scientific team via the inquiry form below or email us directly---we look forward to collaborating with you.

For research use only. Not intended for any clinical use.